Drug intelligence / Profile preview

SVT26

Development stage: Discontinued
Lead developer: Servatus Biopharmaceuticals
Modality: Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Topical

Overview

SVT26 is a live bacterial strain developed by the Australian biotechnology company Servatus as a component of a topical live biotherapeutic product (LBP) consortium for the treatment of atopic dermatitis. Formulated alongside two other bacterial strains, SVT9 and SVT23, in a topical spray, SVT26 is designed to address dysbiosis and immune dysregulation associated with inflammatory skin conditions. The three-strain consortium was evaluated in a single-center, open-label, single-arm exploratory Phase 0 clinical study in Australia, where it was applied twice daily for 21 days to active atopic dermatitis lesions.

Beyond the preview

Go deeper on SVT26.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SVT26.

Explore the full profile